Akari Therapeutics (AKTX) Receivables (2011 - 2013)

Akari Therapeutics has disclosed Receivables across 3 years of filings, most recently posting $6000.0 for Q4 2013.

• Receivables for Q4 2013 came in at $6000.0, down 50.0% year-over-year; the trailing twelve-month figure through Dec 2013 was $6000.0 (down 50.0% YoY), and the FY2013 annual result was $6000.0, down 50.0% from the prior year.
• Receivables came in at $6000.0 for Q4 2013 at Akari Therapeutics, down from $12000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $19000.0 in Q4 2011 to a low of $6000.0 in Q4 2013.
• The 3-year median for Receivables is $12000.0 (2012), against an average of $12333.3.
• Across the five-year window, Receivables sank 36.84% in 2012 and plunged 50.0% in 2013, its largest moves.
• Akari Therapeutics' Receivables stood at $19000.0 in 2011, then sank by 36.84% to $12000.0 in 2012, then slumped by 50.0% to $6000.0 in 2013.
• The last three Receivables figures came in at $6000.0 (Q4 2013), $12000.0 (Q4 2012), and $19000.0 (Q4 2011), per Business Quant data.